Role of organic cation transporters in drug-induced toxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 2, 2011, Pages 159-174

  Ciarimboli, Giuliano ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

cisplatin; metformin; organic cation transporters; toxicity

Indexed keywords

2' DEOXYTUBERCIDIN; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; BLEOMYCIN; CARBOPLATIN; CHOLINE; CIMETIDINE; CISPLATIN; DOPAMINE; ETOPOSIDE; GANCICLOVIR; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVAMISOLE; METFORMIN; MULTIDRUG RESISTANCE PROTEIN 1; NAFAMSTAT MESILATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; ORGANIC CATION TRANSPORTER 4; ORGANIC CATION TRANSPORTER 5; OXALIPLATIN; PHENFORMIN; PROCAINAMIDE; QUINIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT DISEASE; CHILDHOOD CANCER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG TOXICITY; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERGLYCEMIA; LACTIC ACIDOSIS; MEMBRANE TRANSPORT; NEOPLASM; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTOTOXICITY; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS CANCER;

BINDING SITES; DRUG TOXICITY; HUMANS; KIDNEY; MOLECULAR TARGETED THERAPY; ORGANIC CATION TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 79952132912     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.547474     Document Type: Review

References (144)

1. Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 2008;7:205-20
2. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008;38:802-32
3. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194:1481-91 (Pubitemid 44851889)
4. Neuhoff S, Ungell AL, Zamora I, Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res 2003;20:1141-8 (Pubitemid 36951837)
5. Hediger MA, Romero MF, Peng JB, et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 2004;447:465-8 (Pubitemid 38241432)
6. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch 2004;447:666-76 (Pubitemid 38241452)
7. Grundemann D, Gorboulev V, Gambaryan S, et al. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994;372:549-52 A seminal paper describing the cloning of rat OCT1.
8. Gorboulev V, Ulzheimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 1997;16:871-81 The first paper describing the cloning and characterization of human OCT1 and OCT2.
9. Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997;51:913-21 (Pubitemid 27249124)
10. Terashita S, Dresser MJ, Zhang L, et al. Molecular cloning and functional expression of a rabbit renal organic cation transporter. Biochim Biophys Acta 1998;1369:1-6 (Pubitemid 28129251)
11. Schweifer N, Barlow DP. The Lx1 gene maps to mouse chromosome 17 and codes for a protein that is homologous to glucose and polyspecific transmembrane transporters. Mamm Genome 1996;7:735-40 (Pubitemid 126440373)
12. Okuda M, Saito H, Urakami Y, et al. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun 1996;224:500-7 (Pubitemid 26268216)
13. Grundemann D, Babin-Ebell J, Martel F, et al. Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J Biol Chem 1997;272:10408-13 (Pubitemid 27181042)
14. Mooslehner KA, Allen ND. Cloning of the mouse organic cation transporter 2 gene, Slc22a2, from an enhancer-trap transgene integration locus. Mamm Genome 1999;10:218-24 (Pubitemid 29390506)
15. Zhang X, Evans KK, Wright SH. Molecular cloning of rabbit organic cation transporter rbOCT2 and functional comparisons with rbOCT1. Am J Physiol Renal Physiol 2002;283:F124-33
16. Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 2002;13:866-74 A comprehensive analysis of OCT2 distribution in human kidney.
17. Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1998;1:349-51 An important paper reporting the cloning and characterization of OCT3.
18. Kekuda R, Prasad PD, Wu X, et al. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 1998;273:15971-9 (Pubitemid 28311362)
19. Wu X, Kekuda R, Huang W, et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 1998;273:32776-86 (Pubitemid 28557664)
20. Verhaagh S, Schweifer N, Barlow DP, Zwart R. Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics 1999;55:209-18 A demonstration that OCT genes are clustered.
21. Vialou V, Amphoux A, Zwart R, et al. Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 2004;24:2846-51 (Pubitemid 38380963)
22. Vialou V, Balasse L, Callebert J, et al. Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 2008;106:1471-82
23. Baganz NL, Horton RE, Calderon AS, et al. Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci U S A 2008;105:18976-81
24. Wright SH, Dantzler WH. Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 2004;84:987-1049 (Pubitemid 38823772)
25. Koepsell H, Schmitt BM, Gorboulev V. Organic cation transporters. Rev Physiol Biochem Pharmacol 2003;150:36-90
26. Moriyama Y, Hiasa M, Matsumoto T, Omote H. Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica 2008;38:1107-18
27. Tanihara Y, Masuda S, Sato T, et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 2007;74:359-71 (Pubitemid 46890818)
28. Yabuuchi H, Tamai I, Nezu J, et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 1999;289:768-73 (Pubitemid 29191230)
29. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306
30. Ciarimboli G, Schlatter E. Regulation of organic cation transport. Pflugers Arch 2005;449:423-41 A review summarizing regulation mechanisms of OCTs.
31. Eraly SA, Hamilton BA, Nigam SK. Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem Biophys Res Commun 2003;300:333-42 (Pubitemid 38379656)
32. Eraly SA, Monte JC, Nigam SK. Novel slc22 transporter homologs in fly, worm, and human clarify the phylogeny of organic anion and cation transporters. Physiol Genomics 2004;18:12-24 (Pubitemid 39319482)
33. Martel F, Ribeiro L, Calhau C, Azevedo I. Inhibition by levamisole of the organic cation transporter rOCT1 in cultured rat hepatocytes. Pharmacol Res 1999;40:275-9 (Pubitemid 29435728)
34. Chen R, Jonker JW, Nelson JA. Renal organic cation and nucleoside transport. Biochem Pharmacol 2002;64:185-90 (Pubitemid 34775297)
35. Chen R, Nelson JA. Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol 2000;60:215-19 (Pubitemid 30312949)
36. Takeda M, Khamdang S, Narikawa S, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 2002;300:918-24 (Pubitemid 34164996)
37. Dudley AJ, Bleasby K, Brown CD. The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol 2000;131:71-9
38. Khamdang S, Takeda M, Noshiro R, et al. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 2002;303:534-9 (Pubitemid 35231223)
39. Bourdet DL, Pritchard JB, Thakker DR. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 2005;315:1288-97 (Pubitemid 41635417)
40. Hasannejad H, Takeda M, Narikawa S, et al. Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. Eur J Pharmacol 2004;499:45-51 (Pubitemid 39201210)
41. Li Q, Sai Y, Kato Y, et al. Transporter-mediated renal handling of nafamostat mesilate. J Pharm Sci 2004;93:262-72 (Pubitemid 38174249)
42. Ming X, Ju W, Wu H, et al. Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos 2009;37:424-30
43. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005;167:1477-84 The first demonstration of hOCT2 importance for cisplatin uptake.
44. Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010;176:1169-80 The first demonstration of OCT2 importance for cisplatin otoxicity, of OCT2 localization in cochlear structures and of possibility of protecting the ear and the kidney from cisplatin toxicity in vivo by a competition approach at transporter level.
45. Yonezawa A, Masuda S, Nishihara K, et al. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 2005;70:1823-31 (Pubitemid 41612013)
46. Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-86
47. More SS, Li S, Yee SW, et al. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther 2010;9:1058-69 A demonstration of hOCT2 importance for picoplatin uptake.
48. Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66:8847-57 (Pubitemid 44449203)
49. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005;22:255-9 (Pubitemid 40487209)
50. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-86
51. Wang DS, Kusuhara H, Kato Y, et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003;63:844-8 A demonstration of OCT1 importance for metformin side effects.
52. Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-15 (Pubitemid 34787213)
53. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-93 (Pubitemid 9120960)
54. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-46 (Pubitemid 11034446)
55. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659-63 (Pubitemid 28449803)
56. El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223-8 (Pubitemid 30038975)
57. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997;102:99-110 (Pubitemid 27089992)
58. Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987;23:545-51 (Pubitemid 17087957)
59. Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 1983;8:463-95 (Pubitemid 13023843)
60. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-31 Meaning of OCT1 genetic variants for metformin action.
61. Dresser MJ, Xiao G, Leabman MK, et al. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 2002;19:1244-7 (Pubitemid 34985011)
62. Becker ML, Visser LE, van Schaik RH, et al. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009;58:745-9
63. Meyer Zu Schwabedissen HE, Verstuyft C, Kroemer HK, et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010;298:F997-F1005
64. Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 (MATE1) in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 2009;329:185-91
65. Chen L, Pawlikowski B, Schlessinger A, et al. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 2010;20:687-99
66. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-42
67. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23 A review on toxicities induced by platinating agents.
68. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007 (Pubitemid 351543900)
69. Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer 2004;40:2352-4 (Pubitemid 39424946)
70. Urakami Y, Nakamura N, Takahashi K, et al. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett 1999;461:339-42 (Pubitemid 29533359)
71. Filipski KK, Mathijssen RH, Mikkelsen TS, et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009;86:396-402 A paper demonstrating the role of hOCT2 in cisplatin nephrotoxicity and of genetic variants in determining resistance to cisplatin nephrotoxicity.
72. Burger H, Zoumaro-Djayoon A, Boersma AW, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 2010;159:898-908
73. Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-87 (Pubitemid 46963232)
74. Shnitsar V, Eckardt R, Gupta S, et al. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 2009;69:1494-501
75. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009;296:F505-11
76. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234:4-33 (Pubitemid 43343938)
77. Kalow W, Endrenyi L, Tang B. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology 1999;58:281-4 (Pubitemid 29206182)
78. Kerb R, Brinkmann U, Chatskaia N, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002;12:591-5 (Pubitemid 36005667)
79. Leabman MK, Huang CC, DeYoung J, et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003;100:5896-901 Identification and characterization of OCT polymophisms.
80. Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003;100:5902-7 (Pubitemid 36576905)
81. Takeuchi A, Motohashi H, Okuda M, Inui K. Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metab Pharmacokinet 2003;18:409-12
82. Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 2004;313:789-93 (Pubitemid 38021900)
83. Itoda M, Saito Y, Maekawa K, et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet 2004;19:308-12
84. Jonker JW, Wagenaar E, Mol CA, et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 2001;21:5471-7 (Pubitemid 32702451)
85. Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007;52:117-22 (Pubitemid 46185105)
86. Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002;12:395-405 (Pubitemid 34816419)
87. Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008;84:559-62
88. Song IS, Shin HJ, Shin JG. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes. Xenobiotica 2008;38:1252-62
89. Fujita T, Urban TJ, Leabman MK, et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006;95:25-36
90. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-9 (Pubitemid 46676108)
91. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51 (Pubitemid 46026500)
92. Tregouet DA, Konig IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009;41:283-5
93. Sakata T, Anzai N, Kimura T, et al. Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. J Pharmacol Sci 2010;113:263-6
94. Ciarimboli G, Koepsell H, Iordanova M, et al. Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 2005;16:1562-70 Molecular characterization of regulation mechanisms of rOCT1.
95. Gorboulev V, Shatskaya N, Volk C, Koepsell H. Subtype-specific affinity for corticosterone of rat organic cation transporters rOCT1 and rOCT2 depends on three amino acids within the substrate binding region. Mol Pharmacol 2005;67:1612-19 (Pubitemid 40594160)
96. Popp C, Gorboulev V, Muller TD, et al. Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol 2005;67:1600-11 Modeling of rOCT1 binding site and of transporter structure.
97. Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 2004;21:976-81 (Pubitemid 38870147)
98. Eisner C, Faulhaber-Walter R, Wang Y, et al. Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int 2010;77:519-26
99. Tsuruoka S, Ioka T, Wakaumi M, et al. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther 2006;79:389-96
100. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 2007;117:1226-9 (Pubitemid 46718410)
101. Maeda T, Oyabu M, Yotsumoto T, et al. Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats. Drug Metab Dispos 2007;35:1580-6 (Pubitemid 47296051)
102. Urakami Y, Okuda M, Saito H, Inui K. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett 2000;473:173-6 (Pubitemid 30254285)
103. Wilde S, Schlatter E, Koepsell H, et al. Calmodulin-associated post-translational regulation of rat organic cation transporter 2 in the kidney is gender dependent. Cell Mol Life Sci 2009;66:1729-40
104. Muller J, Lips KS, Metzner L, et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005;70:1851-60 (Pubitemid 41612016)
105. Lips KS, Volk C, Schmitt BM, et al. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 2005;33:79-88 (Pubitemid 40961017)
106. Minuesa G, Purcet S, Erkizia I, et al. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther 2008;324:558-67 (Pubitemid 351185862)
107. Kimura N, Masuda S, Katsura T, Inui K. Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochem Pharmacol 2009;77:1429-36
108. Ciarimboli G, Struwe K, Arndt P, et al. Regulation of the human organic cation transporter hOCT1. J Cell Physiol 2004;201:420-8 (Pubitemid 39456441)
109. Lee WK, Reichold M, Edemir B, et al. The organic cation transporters OCT1, 2, and 3 mediate high affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 2009;296:F1504-13
110. Kang HJ, Lee SS, Lee CH, et al. Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters. Drug Metab Dispos 2006;34:1145-51
111. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45 (Pubitemid 39564452)
112. Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258-64
113. Minuesa G, Volk C, Molina-Arcas M, et al. Transport of lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 2009;329:252-61
114. Zhang L, Schaner ME, Giacomini KM. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 1998;286:354-61 (Pubitemid 28318011)
115. Busch AE, Karbach U, Miska D, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 1998;54:342-52 (Pubitemid 28368824)
116. Taubert D, Grimberg G, Stenzel W, Schomig E. Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons. PLoS ONE 2007;2:e385
117. Grundemann D, Hahne C, Berkels R, Schomig E. Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J Pharmacol Exp Ther 2003;304:810-17 (Pubitemid 36152360)
118. Biermann J, Lang D, Gorboulev V, et al. Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol 2006;290:C1521-31
119. Barendt WM, Wright SH. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem 2002;277:22491-6 (Pubitemid 34967222)
120. Ciarimboli G, Holle SK, Vollenbroker B, et al. New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol Pharm 2010; DOI: 10.1021/mp100329u
121. Chen Y, Zhang S, Sorani M, Giacomini KM. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 2007;322:695-700 (Pubitemid 47105798)
122. Grundemann D, Liebich G, Kiefer N, et al. Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 1999;56:1-10 (Pubitemid 29309806)
123. Tamai I, Yabuuchi H, Nezu J, et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 1997;419:107-11 (Pubitemid 28011227)
124. Tamai I, Nakanishi T, Kobayashi D, et al. Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. Mol Pharm 2004;1:57-66
125. McBride BF, Yang T, Liu K, et al. The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol 2009;54:63-71
126. Garrett Q, Xu S, Simmons PA, et al. Expression and localization of carnitine/organic cation transporter OCTN1 and OCTN2 in ocular epithelium. Invest Ophthalmol Vis Sci 2008;49:4844-9
127. Lamhonwah AM, Tein I. Novel localization of OCTN1, an organic cation/carnitine transporter, to mammalian mitochondria. Biochem Biophys Res Commun 2006;345:1315-25 (Pubitemid 43833440)
128. Grundemann D, Harlfinger S, Golz S, et al. Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A 2005;102:5256-61
129. Urban TJ, Brown C, Castro RA, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 2008;83:416-21 (Pubitemid 351272627)
130. Nakamura T, Nakanishi T, Haruta T, et al. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm 2010;7:187-95
131. Wu X, Prasad PD, Leibach FH, Ganapathy V. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 1998;246:589-95 (Pubitemid 28420901)
132. Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998;273:20378-82 (Pubitemid 28377603)
133. Kido Y, Tamai I, Ohnari A, et al. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 2001;79:959-69 (Pubitemid 33117074)
134. Wagner CA, Lukewille U, Kaltenbach S, et al. Functional and pharmacological characterization of human Na+-carnitine cotransporter hOCTN2. Am J Physiol Renal Physiol 2000;279:F584-91
135. Ganapathy ME, Huang W, Rajan DP, et al. β-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 2000;275:1699-707 (Pubitemid 30060789)
136. Hu S, Franke RM, Filipski KK, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14:3141-8
137. Grigat S, Fork C, Bach M, et al. The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. Drug Metab Dispos 2009;37:330-7
138. Grube M, Meyer Zu Schwabedissen HE, Prager D, et al. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 2006;113:1114-22
139. Ohashi R, Tamai I, Yabuuchi H, et al. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 1999;291:778-84 (Pubitemid 29503553)
140. Otsuka M, Matsumoto T, Morimoto R, et al. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005;102:17923-8 A description of the role of MATE transporter in the excretion of organic cations.
141. Ohta KY, Inoue K, Yasujima T, et al. Functional characteristics of two human MATE transporters: kinetics of cimetidine transport and profiles of inhibition by various compounds. J Pharm Pharm Sci 2009;12:388-96
142. Yasujima T, Ohta KY, Inoue K, et al. Evaluation of 4′,6-diamidino- 2-phenylindole as a fluorescent probe substrate for rapid assays of the functionality of human multidrug and toxin extrusion proteins. Drug Metab Dispos 2010;38:715-21
143. Matsushima S, Maeda K, Inoue K, et al. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 2009;37:555-9
144. Masuda S, Terada T, Yonezawa A, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17:2127-35 (Pubitemid 44141902)